Tonix Pharmaceuticals Holding Corp.
TNXPUS売上高
$13M
百万USD
営業利益
$-126M
百万USD
純利益
$-124M
百万USD
ROE
-50.6%
最新FY
EPS
$-14.57
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | - | $-21M | - |
| FY2021 | Q2 | - | $-24M | - |
| FY2021 | Q3 | - | $-19M | - |
| FY2021 | FY | - | $-92M | - |
| FY2022 | Q1 | - | $-26M | $-0.05 |
| FY2022 | Q2 | - | $-23M | $-1.22 |
| FY2022 | Q3 | - | $-29M | $-0.69 |
| FY2022 | FY | - | $-110M | $-3.27 |
| FY2023 | Q1 | - | $-33M | $-0.52 |
| FY2023 | Q2 | - | $-28M | $-2.68 |
| FY2023 | Q3 | $4M | $-28M | $-1.83 |
| FY2023 | FY | $8M | $-117M | $-6.85 |
| FY2024 | Q1 | $2M | $-15M | $-0.18 |
| FY2024 | Q2 | $2M | $-79M | $-19.28 |
| FY2024 | Q3 | $3M | $-14M | $-0.23 |
| FY2024 | FY | $10M | $-130M | $-176.60 |
| FY2025 | Q1 | $2M | $-17M | $-2.84 |
| FY2025 | Q2 | $2M | $-28M | $-3.86 |
| FY2025 | Q3 | $3M | $-32M | $-3.59 |
| FY2025 | FY | $13M | $-124M | $-14.57 |
| FY2026 | Q1 | $7M | $-40M | $-2.93 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | - | - | - | - | $8M | $10M | $13M |
| 営業利益 | $-39M | $-21M | $-26M | $-29M | $-51M | $-92M | $-112M | $-118M | $-137M | $-126M |
| 純利益 | $-39M | $-21M | $-26M | $-29M | $-50M | $-92M | $-110M | $-117M | $-130M | $-124M |
| 総資産 | $28M | $27M | $26M | $15M | $98M | $241M | $226M | $154M | $163M | $277M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $25M | $25M | $24M | $9M | $88M | $219M | $207M | $106M | $140M | $245M |
| 営業CF | - | $-19M | $-24M | $-27M | $-49M | $-76M | $-98M | $-102M | $-61M | $-100M |
| EPS | - | - | - | - | - | - | $-3.27 | $-6.85 | $-176.60 | $-14.57 |
| BPS | $3.39 | $3.14 | $3.89 | $0.19 | $0.27 | $0.41 | $3.31 | $1.25 | $21.69 | $18.29 |
| ROE | -153.2% | -85.8% | -110.2% | -303.9% | -57.6% | -42.2% | -53.2% | -110.6% | -93.2% | -50.6% |